STLN plunged from a $6.70 prior close to $4.135, a -38.21% drop, during regular Nasdaq market hours. The selloff followed Q3 results released after the prior close: a wider-than-expected loss of -$0.13 per share (vs -$0.07 consensus) and lowered FY2026 revenue guidance of $650M-$660M (vs $665M consensus), including a cut to its capitated revenue outlook.
AIRS collapsed during regular trading hours, falling from a prior close of $1.44 to about $0.65, a drop of -54.86%. The plunge followed Q3 2026 results that badly missed estimates — a -$0.10 per-share loss versus roughly -$0.02 expected and revenue of $31.9M versus about $35.2M — along with a sharp cut to full-year guidance.
AMN shares fell during regular trading, sliding from a prior close of $47.42 to about $40.46 — a drop of -14.68%. The selloff followed Q3 2026 results released after the Nov 5 close: adjusted EPS of $1.16 beat the $0.22 consensus, but the beat was flattered by a one-time $51M strike reserve release, and Q4 guidance was weak (roughly breakeven operating margin; total revenue down 10-12% year over year).
BKD fell -13.64% during regular market hours, sliding from a previous close of $10.81 to about $9.34. The drop followed Q3 2026 results released before the open: EPS of -$0.06 missed the -$0.03 consensus and revenue of $712.1M fell short of estimates.
The Joint Corp. (JYNT) fell -6.92% during regular trading, sliding from a prior close of $7.37 to $6.86. The move followed Q3 results released after the Nov 5 close: revenue of $13.6M missed consensus and EPS came in below estimates, alongside a cut to full-year guidance.
Astrana Health (ASTH) dropped -15.41% during regular trading hours, falling from its prior close of $39.01 to $33.00. The selloff followed Q3 2026 results released after the November 5 close: adjusted EPS of $0.71 missed the ~$0.88 consensus, and Q4 revenue guidance of roughly $989 million (midpoint) came in below estimates, alongside worsening Medicaid cost trends and a softer medium-term EBITDA growth outlook.
Brookdale Senior Living (BKD) fell during regular trading hours, dropping from a prior close of $10.81 to $10.02, a -7.31% decline. The drop followed its Q3 2026 results released before the open: EPS of -$0.06 missed the -$0.03 consensus and revenue of $712.1M fell short of estimates.
The Joint Corp. reported third-quarter 2026 revenue of $13.6 million, up about 1% year over year but below consensus estimates near $14.85 million. System-wide sales declined 3.1% to $123.3 million, while comparable sales (comp sales) improved to -1.9% from -2.8% in the prior quarter.
Revenue came in at $152.9 million , down 11% year over year from $172.1 million, as a shrinking core subscription base continued to weigh on the top line. Net income turned positive at $15.1 million , marking the company's second consecutive profitable quarter since emerging from its 2025 financial reorganization.
Third quarter 2026 revenue rose 24.3% year over year to $169.8 million, narrowly topping consensus estimates near $168.7 million. Net loss narrowed to $15.7 million, or $0.13 per share, from $16.5 million, or $0.14 per share, a year earlier, but the loss was wider than the roughly $0.05–$0.07 per share analysts had modeled.
Nutex Health reported full-year 2025 revenue of $875.3 million, an 82% increase from $479.9 million in 2024. Fourth quarter 2025 revenue fell 41.1% year over year to $151.7 million, driven by a one-time $55 million revenue reduction tied to an arbitration claims true-up.
Third quarter 2026 revenue reached $210.2 million , up 114% from $98.0 million a year ago and above the roughly $192.9 million consensus estimate, driven by the CNL Healthcare Properties (CHP) merger. On a GAAP (Generally Accepted Accounting Principles) basis, the company reported a net loss of $0.72 per share ; adjusted results also came in below the roughly $0.52 per-share loss analysts had expected.
Astrana Health (ASTH) is scheduled to report third-quarter 2026 results on Thursday, November 5, 2026, after the market close. Wall Street expects revenue of roughly $1.02 billion, near the midpoint of the company's own guidance of $1.0 billion to $1.03 billion.
AMN Healthcare Services reported third quarter 2026 revenue of $717.3 million, up 13% year over year and well above the roughly $649 million consensus estimate. Adjusted earnings per share (EPS) came in at $1.16, far exceeding the analyst consensus of $0.23, while GAAP (Generally Accepted Accounting Principles) net income reached $0.83 per share.
Third quarter 2026 revenue came in at $371.07 million, down 1.7% year over year, as Inflation Reduction Act (IRA) drug-price reductions masked otherwise solid underlying growth. Adjusted earnings per share (EPS) of $0.33 topped the $0.32 consensus estimate, while revenue also exceeded the roughly $366 million analyst expectation.
Revenue reached $622.1 million , up 8.6% year over year and above the consensus estimate of about $605.5 million. Adjusted earnings per share (EPS, or profit divided by shares outstanding) came in at $0.52 , beating the consensus estimate of $0.44.
Revenue rose 25% year over year to $455.9 million, exceeding Wall Street consensus estimates of roughly $431.7 million. Diluted earnings per share (EPS) came in at $0.06, double the $0.03 consensus estimate and up from essentially breakeven a year earlier.
Acadia Healthcare (ACHC) jumped +7.78% during regular market hours, climbing from a $32.25 prior close to $34.76. The advance extends the post-earnings surge after Q3 results beat estimates, with adjusted EPS of $0.60 topping the $0.46 consensus alongside raised full-year guidance.
USPH jumped from a previous close of $89.18 to a latest price of $97.19, a +8.98% (+$8.01) gain, during regular market hours. The rally followed strong Q3 2026 results released after the Nov 4 close — adjusted EPS of $0.80 beat consensus of $0.73 and revenue of $222.6M beat the $214.3M estimate.
AGL shares jumped in regular trading, climbing from the prior close of $96.23 to roughly $107.51 intraday, a gain of +11.72%. The move is a reaction to Q3 2026 results released after Tuesday's close: EPS of $1.97 versus consensus for a loss, revenue of $1.52B beating the $1.46B estimate, and raised full-year 2026 guidance.